FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has granted priority review to giredestrant for the treatment of ER+/HER2- breast cancer. This designation indicates that the review process for giredestrant will be expedited. The priority review status suggests that giredestrant may offer a significant benefit for patients with this type of breast cancer.